HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026
Watch: HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026

Listen to Oncology Here & Now
Regulatory decisions and trial results, in the order we post them.
Dr. Vilma Barcia. Trial result. ESMO 2026. Video.
Watch: HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026

Genitourinary. ESMO 2026.
LITESPARK-011 Dr. Daniel HengGenitourinary. Dr. Daniel Heng. ESMO 2026.
VOLGA Phase 3 TrialDr. Tom PowlesGenitourinary. Dr. Tom Powles. ESMO 2026.

Breast. Dr. Gil Morgan. ESMO 2026.
TOP-1 TrialDr. Elisabetta BonzanoBreast. Dr. Elisabetta Bonzano. ESMO 2026.
ESMO 2026Sara Coca MembribesGenitourinary. Sara Coca Membribes. ESMO 2026.
Gastrointestinal. October 19, 2026.
Gastrointestinal. FDA. October 12, 2026.
Breast. FDA. October 7, 2026.
Genitourinary. European Urology. October 5, 2026.
Breast. Study result. Radiotherapy & Oncology. October 15, 2026.
Genitourinary. Study result. Nature Reviews Urology. October 15, 2026.
Breast. Study result. NEJM. October 12, 2026.
Genitourinary. Study result. Journal of Clinical Oncology. October 12, 2026.
Breast. Study result. NEJM. October 9, 2026.
Lung and thoracic. Study result. Journal if Thoracic Oncology. October 7, 2026.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.